Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Peripheral, UnspecifiedT-Cell Prolymphocyte LeukemiaSubgroupJAK2 rearrangementICD10C84.4C84.8C86.5C91.6-MeSHImmunoblastic LymphadenopathyLeukemia, Prolymphocytic, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralSequenceALEM(3/10/30), T-PLL, C1 (PID1548) -|- ALEM30, C2+ (PID1549)PNTS4, T-PLL, C1-4 (PID1562) -|- C5-8 (PID1563)PNTS4/ALEM(3/10/30), T-PLL, C1 (PID1566) -|- C2-4 (PID1567) -|- C5-8 (PID1568)ChemotherapyChemo-substanceAlemtuzumabBendamustineCyclophosphamideFludarabineMitoxantronePentostatinRuxolitinibChemo-substanceAlemtuzumabBendamustineCyclophosphamideFludarabineMitoxantronePentostatinRuxolitinibChemo-substanceAlemtuzumabBendamustineCyclophosphamideFludarabineMitoxantronePentostatinRuxolitinibChemo-substanceAlemtuzumabBendamustineCyclophosphamideFludarabineMitoxantronePentostatinRuxolitinibNo. Substances123 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances4678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityCMV Infection (asympt. + sympt.)DiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityInfectionsNephrotoxicityNeutropeniaPneumoniaPyrexiaSepsisThrombocytopenia below 50 000/µlTumor Lysis Syndrome only studiesPublicationAuthorDearden CHerbaux CHopfinger GMercieca JMoskowitz AJ Ravandi FDiseaseneudiagnostizierte, rezidivierte oder refraktäre T-PLL, PTCL, HSTCL, extranodales killer/T-Zell Lymphom, ECOG 0-2neudiagnostizierte, rezidivierte oder refraktäre T-PLL, PTCL, HSTCL, extranodales NK/T-Zell Lymphom, ECOG 0-2Peripheres T- oder NK-Zell Lymphom, kutanes T-Zell Lymphom (Stadium IB oder höher), T-PLLT-PLL, Erst- und ZweitlinieT-PLL, T-NHL, ATLL, Sézary Syndrom, Erstlinie und RezidivtherapieT-Zell Prolymphozytenleukämie, Erst-, Zweit-, oder Drittlinie, ECOG 0-3T-Zell Prolymphozytenleukämie, Erst- und ZweitlinieT-Zell Prolymphozytenleukämie, mehrere Linien möglich, ECOG 0-3OriginAcademic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London, UKDepartment of Internal Medicine III with Hematology, Medical Oncology, Paracelsus Medical University Salzburg, AustriaMemorial Sloan-Kettering Cancer Center, New York, NYService des Maladies du Sang, Centre Hospitalier Regional et Universitaire de Lille, LilleThe Royal Marsden National Health Service (NHS) Trust, Sutton, United KingdomThe University of Texas M. D. Anderson Cancer Center, Houston, TXProtocols in Revision 10 protocols foundProtocols under revision.Alemtuzumab (3/10/30), T-Cell Prolymphocyte Leukemia, Cycle 1 (PID1548 V1.0)Alemtuzumab 30, T-prolymphocytic leukemia, cycle 2+ (PID1549 V1.0)Bendamustine 120, T-Cell Prolymphocyte Leukemia (PID1561 V1.0)Fludarabine 25 / Cyclophosphamide 200 / Mitoxantrone 8, T-Cell Prolymphocyte Leukemia (PID1560 V1.0)Pentostatin 4 / Alemtuzumab (3/10/30), T-Cell Prolymphocyte Leukemia, Cycle 1 (PID1566 V1.0)Pentostatin 4 / Alemtuzumab 30, T-Cell Prolymphocyte Leukemia, Cycle 2-4 (PID1567 V1.0)Pentostatin 4 / Alemtuzumab 30, T-Cell Prolymphocyte Leukemia, Cycle 5-8 (PID1568 V1.0)Pentostatin 4, T-Cell Prolymphocyte Leukemia, Cycle 1-4 (PID1562 V1.0)Pentostatin 4, T-Cell Prolymphocyte Leukemia, Cycle 5-8 (PID1563 V1.0)Ruxolitinib 20, T-Cell Lymphoma / T-Cell Prolymphocyte Leukemia (PID2478 V1.0)
